BTIG Reaffirms Their Hold Rating on BELLUS Health (BLU)
RBC Capital Sticks to Their Hold Rating for BELLUS Health (BLU)
RBC Capital Reiterates Sector Perform on BELLUS Health, Maintains $14.75 Price Target
Jefferies Downgrades BELLUS Health to Hold, Lowers Price Target to $14.75
RBC Downgrades BELLUS Health to Sector Perform From Outperform, Cuts Price Target to $14.75 From $21 Amid GSK Deal; Speculative Risk Kept
TD Cowen Downgrades BELLUS Health to Market Perform From Outperform, Adjusts Price Target to $14.75 From $15
Evercore ISI Group Downgrades BELLUS Health to In-Line, Lowers Price Target to $14.75
LifeSci Capital Reaffirms Their Hold Rating on BELLUS Health (BLU)
LifeSci Capital Sticks to Their Buy Rating for BELLUS Health (BLU)
Analysts Offer Insights on Healthcare Companies: Selecta Biosciences (SELB) and BELLUS Health (BLU)
H.C. Wainwright Reaffirms Their Buy Rating on BELLUS Health (BLU)
HC Wainwright & Co. Reiterates Buy on BELLUS Health, Maintains $20 Price Target
BELLUS Health (BLU) Receives a Buy From BTIG
Analysts Offer Insights on Healthcare Companies: Innate Pharma SA (OtherIPHYF) and BELLUS Health (BLU)
RBC Raises Price Target on BELLUS Health to $21 From $19, Maintains Outperform, Speculative Risk
BELLUS Health Analyst Ratings
RBC Capital Maintains Outperform on BELLUS Health, Raises Price Target to $21
BELLUS Health Analyst Ratings
Jefferies Maintains Buy on BELLUS Health, Raises Price Target to $21
Jefferies Adjusts BELLUS Health's Price Target to $21 From $14, Reiterates Buy Rating
No Data